Medical treatment of benign prostatic hyperplasia

Authors

  • F. SÁNCHEZ DE MEDINA

Abstract

Benign prostatic hyperplasia is a nonmalignant enlargement of the pros tate. This

condition is very common in men over sixty years of age and causes bladder outflow

osbstrucion. There are also irritative symptomes produced by urethral hypertonia of

neurologycal origin through alpha-l-adrenergic receptors. Androgenic suppressión is used

to treat the enlargement of the prostate whereas irritative symptomes are treated with

alpha-I-adrenoreceptor antagonists. Finasteride blocks the conversión of testosterone to

dihydrotestosterone, which is the active fonn of the honnone in the pros tate. Alfuzosin

is an alpha-l-adrenoreceptor antagonist in the genitourinary tract.

Downloads

Download data is not yet available.

References

Hiperplasia benigna de próstata: tratamiento". Boletín Terapéutico Andaluz, 1993, vol. 9,
n. 1:1-4.

OESTERLING, J. E.: "Benign Prostatic Hpyperplasia. Medical and minimally invasive
treatment options". The New England Journal 01 Medicine, 1995, 332:99-108.

"Nuevos medicamentos comercializados en España: Finasterida". Panorama Actual del
Medicamento, 1993, 17:521-529.

STONER, E., GREGOIRE, S. and ROUND, E.: "Clinical development of finasteride".
Drugs 01 Today, 1993, 29:351-361.

PETERS, D. H. and SORKlN, E. M.: "Finasteride. A review of its potential in the
treatment of benign prostatic hyperplasia". Drugs, 1993, 45: 177-208.

WILDE, M. l ., FIITON, A. and MeTA VISH, D.: "Alfuzosin. A review of its pharmaeodynamie
and pharmacokinetics properties and therapeutic potential in benign prostatic hyperplasia".
Drugs, 1993, 45:410-429.

Downloads

Published

1995-06-20

How to Cite

1.
SÁNCHEZ DE MEDINA F. Medical treatment of benign prostatic hyperplasia. Ars Pharm [Internet]. 1995 Jun. 20 [cited 2024 Aug. 24];36(2):281-3. Available from: https://revistaseug.ugr.es/index.php/ars/article/view/21917

Issue

Vol. 36 No. 2 (1995)

Section

Original Articles

License

The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:

  1. The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.

b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.

c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).